|
Jul 26
|
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
|
|
Jul 26
|
Calliditas’ Phase IIb trial of PBC treatment meets primary endpoint
|
|
Jul 26
|
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
|
|
May 2
|
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
|
|
Apr 18
|
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
|
|
Apr 16
|
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
|
|
Dec 27
|
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital
|
|
Dec 20
|
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
|
|
Dec 1
|
Calliditas announces additions to the management team
|
|
Nov 30
|
Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome
|
|
Oct 5
|
European Medicines Agency Committee for Orphan Medicinal Products provides positive opinion on Calliditas' application for setanaxib in Alport syndrome
|
|
Oct 3
|
Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy
|
|
Aug 21
|
Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review
|
|
Aug 21
|
Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy
|